Boese Martin, Berman Rina, Radford Kennett, Johnson Luke R, Choi Kwang
Daniel K. Inouye Graduate School of Nursing, Uniformed Services University, Bethesda, MD, United States.
Center for the Study of Traumatic Stress, Uniformed Services University, Bethesda, MD, United States.
Front Neurosci. 2025 Apr 30;19:1546460. doi: 10.3389/fnins.2025.1546460. eCollection 2025.
Ketamine, a multimodal dissociative anesthetic, is widely used as a trauma analgesic in emergency situations. Ketamine is also used to treat psychiatric disorders due to its broad application potential, including treatment-resistant major depression. However, its impacts on the development of post-traumatic stress disorder (PTSD) and its potential as a treatment for PTSD are controversial. PTSD is marked by persistent and intrusive memories of traumatic event(s) and re-experiencing of the traumatic memories when exposed to trauma-related stimuli. Individuals with PTSD are often treated with prolonged exposure therapy (PE), in which they are gradually exposed to stimuli that remind them of the previous traumatic memory. If successful, they may learn that the previously traumatic stimuli are no longer threatening, a process known as fear extinction. Although fear extinction can be studied in laboratory animals, previous preclinical literature on the effects of ketamine on fear extinction has been inconsistent.
Thus, we summarized the existing preclinical literature examining effects of ketamine on fear extinction and its potential molecular mechanisms.
Studies found that ketamine may enhance, impair, have no effect, or have mixed effects on fear extinction. These discrepancies may be attributed to differences in dosage, route, and timing of ketamine administration.
We conclude the review with recommendations for future research on ketamine and PTSD such as the inclusion of more female subjects, clinically relevant doses and routes of ketamine administration, and more comprehensive behavioral assays that are relevant to PTSD in humans to enhance translation between preclinical and clinical research.
氯胺酮是一种多模式解离麻醉剂,在紧急情况下广泛用作创伤镇痛剂。由于其广泛的应用潜力,包括治疗难治性重度抑郁症,氯胺酮也被用于治疗精神疾病。然而,其对创伤后应激障碍(PTSD)发展的影响及其作为PTSD治疗方法的潜力存在争议。PTSD的特征是对创伤事件的持续且侵入性的记忆,以及在接触与创伤相关的刺激时重新体验创伤记忆。PTSD患者通常接受延长暴露疗法(PE)治疗,在此过程中他们会逐渐接触到使他们想起先前创伤记忆的刺激。如果成功,他们可能会了解到先前的创伤性刺激不再构成威胁,这一过程称为恐惧消退。尽管可以在实验动物中研究恐惧消退,但先前关于氯胺酮对恐惧消退影响的临床前文献并不一致。
因此,我们总结了现有的临床前文献,研究氯胺酮对恐惧消退的影响及其潜在的分子机制。
研究发现氯胺酮可能增强、损害、对恐惧消退无影响或产生混合效应。这些差异可能归因于氯胺酮给药的剂量、途径和时间的不同。
我们在综述结尾对氯胺酮和PTSD的未来研究提出建议,例如纳入更多女性受试者、使用与临床相关的氯胺酮给药剂量和途径,以及采用更全面的与人类PTSD相关的行为测定方法,以加强临床前研究与临床研究之间的转化。